Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219711 | 1.00 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL28416331 | 1.00 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL4391077 | 1.00 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL14268474 | 1.00 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL28416330 | 0.87 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL30573245 | 0.84 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL12955979 | 0.82 | L3MBTL1 (0.44) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL22814872 | 0.76 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL20017047 | 0.76 | L3MBTL1 (0.51) | L3MBTL1MEN1KMT2AGAATYR | |
| SCHEMBL8828821 | 0.76 | GAA (0.54) | L3MBTL1MEN1KMT2AGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036229-B2 | Use of phosphorylated heptose compounds | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036229-B2 | Use of phosphorylated heptose compounds | PPP6C, PFKFB1, PFKFB2 | L3MBTL1 3142/4885MEN1 4650/4885KMT2A 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.